The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation
CGCarina Gøtestam SkorpenMHMaria HoeltzenbeinATAnǵela TincaniRFRebecca Fischer‐BetzÉÉÉlisabeth Éléfant
Norwegian University of Science and Technology · Ålesund Hospital · +26 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,050
total citations
- FWCI
- 93.77
- Percentile
- 100%
- References
- 104
Citations per year
Authors
20- CGCarina Gøtestam Skorpen
Norwegian University of Science and Technology, Ålesund Hospital, St Olav's University Hospital
- MHMaria Hoeltzenbein
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
- ATAnǵela Tincani
University of Brescia
- RFRebecca Fischer‐Betz
Düsseldorf University Hospital, Heinrich Heine University Düsseldorf
- ÉÉÉlisabeth Éléfant
Sorbonne Université, Hôpital Armand-Trousseau
Topics & keywords
Topics
Keywords
- Medicine
- Pregnancy
- Rituximab
- Tocilizumab
- Discontinuation
- Sulfasalazine
- Azathioprine
- Intensive care medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.